Skip to content
TrialScanner

NCT04130997

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Phase 3Active, not recruitingTGTXLead

Registry record

Lead sponsor
TG Therapeutics, Inc.
Conditions
Relapsing Multiple Sclerosis (RMS)
Primary completion
May 31, 2032Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT04130997 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.